Cellectis S.A. (NASDAQ:CLLS) Short Interest Down 55.0% in October

Cellectis S.A. (NASDAQ:CLLS) was the target of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 156,200 shares, a decline of 55.0% from the October 15th total of 346,800 shares. Based on an average daily trading volume, of 43,600 shares, the days-to-cover ratio is currently 3.6 days.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on CLLS shares. StockNews.com began coverage on Cellectis in a report on Wednesday. They issued a “sell” rating for the company. Barclays cut their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Trading Down 3.5 %

Shares of Cellectis stock traded down $0.07 during mid-day trading on Thursday, hitting $1.91. 20,551 shares of the stock were exchanged, compared to its average volume of 50,054. The stock has a market capitalization of $106.17 million, a price-to-earnings ratio of -1.52 and a beta of 3.10. Cellectis has a twelve month low of $1.70 and a twelve month high of $3.77. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a 50-day simple moving average of $2.02 and a 200 day simple moving average of $2.25.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The firm had revenue of $18.05 million for the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same quarter last year, the business posted ($0.31) EPS. Research analysts forecast that Cellectis will post -0.46 EPS for the current year.

Institutional Trading of Cellectis

A number of hedge funds have recently added to or reduced their stakes in CLLS. Long Focus Capital Management LLC lifted its holdings in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares during the period. First Affirmative Financial Network acquired a new position in shares of Cellectis in the 3rd quarter worth $45,000. XTX Topco Ltd purchased a new stake in shares of Cellectis in the 2nd quarter valued at approximately $29,000. Finally, Principal Financial Group Inc. boosted its position in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after buying an additional 12,467 shares during the period. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.